The conserved mechanisms underlying different types of chronic pain
不同类型慢性疼痛的保守机制
基本信息
- 批准号:10677714
- 负责人:
- 金额:$ 44.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:ActinsAntisense OligonucleotidesBrainClinicCre driverCytoskeletal ModelingDendritic SpinesDevelopmentDiabetes MellitusGrowthHeterogeneityHypersensitivityInflammationLinkLoxP-flanked alleleMediatingModelingMolecularMorphogenesisMusNatureNeurotrophic Tyrosine Kinase Receptor Type 2NociceptionPathologicPeripheralPeripheral nerve injuryPlayPolymersPopulationPosterior Horn CellsRattusResearchRodent ModelRoleSignal PathwaySignal TransductionSignaling ProteinSpinalSpinal nerve structureSynapsesSynaptic PotentialsSynaptic plasticityTestingTherapeutic EffectTransgenic OrganismsTranslatingVertebral columnViral Vectorcentral sensitizationchemotherapychronic painchronic pain managementchronic painful conditiondensitydorsal horneffective therapyexcitatory neuronfunctional plasticitygenetic manipulationinflammatory painlink proteinnerve injuryneuralnew therapeutic targetpain processingpainful neuropathypolymerizationpreventrho GTP-Binding Proteinsspared nervetargeted treatmenttherapeutic target
项目摘要
PROJECT SUMMARY/ABSTRACT
The primary objective of this proposal is to determine the conserved mechanism that underlies the development
of different types of chronic pain and identify a tractable target with broad implications for therapy. Despite diverse
pathological triggers and different upstream signaling pathways, nociceptive activity-induced functional and
structural plasticity in the spinal dorsal horn serves as the common neural substrate for the different types of
chronic pain. However, it remains unclear which molecular mechanisms orchestrate structural and functional
plasticity in the spinal dorsal horn and whether these mechanisms are conserved across the different types of
chronic pain. Rho GTPases (e.g., Rac1 and RhoA) play essential roles in dendritic spine morphogenesis and
synaptic plasticity by controlling actin cytoskeleton organization. In particular, Rac1 promotes the formation,
growth, and stabilization of spines and synapses. We previously identified Tiam1 as a critical regulator of Rac1-
dependent spine morphogenesis in brain development. Tiam1 is activated by synaptic NMDARs and TrkB
receptors and mediates their effects on actin and spine remodeling. During the pain processing, NMDARs and
TrkB receptors-mediated central sensitization in the spinal dorsal horn are critically involved in chronic pain
hypersensitivity, and Rac1-dependent increases in the size and density of dendritic spines account for the long-
term nature of chronic pain. Our preliminary studies found that Tiam1 was activated in the spinal dorsal horn
under neuropathic pain conditions and modulated synaptic remodeling by promoting peripheral nerve injury-
induced actin polymerization and synaptic NMDAR stabilization. Moreover, Tiam1 deletion from excitatory
neurons or spinal dorsal horn neurons prevented chronic pain development triggered by peripheral nerve injury,
chemotherapy, diabetes, and inflammation. In this proposal, we will test our central hypothesis that Tiam1 links
nociceptive activity-activated NMDARs and TrkB receptors to Rac1 signaling, orchestrating synaptic structural
plasticity via actin cytoskeleton reorganization and functional plasticity via synaptic NMDAR stabilization in
excitatory neuron populations in the spinal dorsal horn, which serves as a conserved mechanism underlying the
development of different types of chronic pain and can be targeted for therapeutic chronic pain intervention. We
will pursue the following three specific aims: 1) Identify Tiam1’s convergent function in different types of chronic
pain; 2) Elucidate the mechanisms by which Tiam1 contributes to different types of chronic pain; 3) Validate
spinal Tiam1 as a therapeutic target for the treatment of chronic pain. At the completion of this project, we will
uncover a conserved mechanism that underlies the development of different types of chronic pain and identify a
novel therapeutic target that could be translated into the clinic to treat chronic pain with broad implications.
项目摘要/摘要
这项建议的主要目标是确定作为发展基础的保守机制
评估不同类型的慢性疼痛,并确定一个易于处理的目标,对治疗具有广泛的影响。尽管差异很大
病理触发和不同的上游信号通路,伤害性活动诱导的功能性和
脊髓背角的结构可塑性是不同类型脊髓损伤的共同神经基质。
慢性疼痛。然而,目前还不清楚哪些分子机制协调结构和功能
脊髓背角的可塑性以及这些机制是否在不同类型的
慢性疼痛。Rho GTP酶(如rac1和RhoA)在树突棘的形态发生和
通过控制肌动蛋白细胞骨架组织的突触可塑性。特别是,rac1促进了细胞的形成,
脊椎和突触的生长和稳定。我们之前发现Tiam1是rac1的关键调节因子-
脑发育中的脊椎形态发生依赖。Tiam1被突触NMDAR和TrkB激活
受体,并介导其对肌动蛋白和脊柱重塑的影响。在疼痛处理过程中,NMDAR和
TrkB受体介导的脊髓背角中枢敏感化与慢性疼痛密切相关
树突棘的大小和密度的增加是由过敏性和Rac1依赖性增加引起的。
慢性疼痛的术语性质。我们的初步研究发现,Tiam1在脊髓背角被激活
在神经病理性疼痛条件下,通过促进周围神经损伤来调节突触重塑-
诱导肌动蛋白聚合和突触NMDAR稳定化。此外,Tiam1从兴奋性基因中缺失
神经元或脊髓背角神经元防止由周围神经损伤引发的慢性疼痛发展,
化疗、糖尿病和炎症。在这个提案中,我们将测试我们的中心假设,即Tiam1链接
伤害性活动-激活NMDAR和TrkB受体对rac1信号,协调突触结构
肌动蛋白骨架重组的可塑性和突触NMDAR稳定的功能可塑性
脊髓背角内的兴奋性神经元群体,这是一种保守的机制
不同类型的慢性疼痛的发展,并可作为治疗慢性疼痛干预的靶点。我们
将追求以下三个具体目标:1)确定天津市S在不同类型慢性肾衰患者中的收敛功能
疼痛;2)阐明Tiam1对不同类型慢性疼痛的作用机制;3)验证
脊髓Tiam1作为治疗慢性疼痛的靶点。在这个项目完成后,我们将
揭示不同类型慢性疼痛形成的保守机制,并找出
新的治疗靶点,可转化为临床治疗慢性疼痛,具有广泛的意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lingyong Li其他文献
Lingyong Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lingyong Li', 18)}}的其他基金
Targeting Tiam1-mediated synaptic plasticity for the relief of opioid tolerance
靶向 Tiam1 介导的突触可塑性以缓解阿片类药物耐受
- 批准号:
10800301 - 财政年份:2023
- 资助金额:
$ 44.26万 - 项目类别:
Multi-modal cell type atlases of somatosensory spinal cord neurons
体感脊髓神经元多模态细胞类型图谱
- 批准号:
10743857 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Targeting Tiam1-mediated synaptic plasticity for the relief of opioid tolerance
靶向 Tiam1 介导的突触可塑性以缓解阿片类药物耐受
- 批准号:
10512217 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Multi-modal cell type atlases of somatosensory spinal cord neurons
体感脊髓神经元多模态细胞类型图谱
- 批准号:
10508739 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Alternative polyadenylation(APA) mechanisms of comorbid mood disorders in chronic pain
慢性疼痛共病情绪障碍的替代多聚腺苷酸化(APA)机制
- 批准号:
10572902 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
The conserved mechanisms underlying different types of chronic pain
不同类型慢性疼痛的保守机制
- 批准号:
10747177 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
相似海外基金
Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
开发反义寡核苷酸来调节γ纤维蛋白原水平
- 批准号:
10759950 - 财政年份:2023
- 资助金额:
$ 44.26万 - 项目类别:
Inducing H3F3A exon skipping with antisense oligonucleotides as an approach to treat diffuse intrinsic pontine glioma
用反义寡核苷酸诱导 H3F3A 外显子跳跃作为治疗弥漫性内源性脑桥胶质瘤的方法
- 批准号:
10677284 - 财政年份:2023
- 资助金额:
$ 44.26万 - 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
- 批准号:
10464020 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy
使用反义寡核苷酸促进成人海马神经发生作为阿尔茨海默氏病的治疗
- 批准号:
10484703 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Strategy for specific delivery of antisense oligonucleotides to T cells
将反义寡核苷酸特异性递送至 T 细胞的策略
- 批准号:
10547347 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10806783 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10689248 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10501862 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
- 批准号:
10623180 - 财政年份:2022
- 资助金额:
$ 44.26万 - 项目类别:
Identifying binding partners, biological substrates and antisense oligonucleotides regulating expression of short and long ACE2.
识别调节短和长 ACE2 表达的结合伴侣、生物底物和反义寡核苷酸。
- 批准号:
BB/V019848/1 - 财政年份:2021
- 资助金额:
$ 44.26万 - 项目类别:
Research Grant